Romagnoli T, Ortolani B, Sanz JM, et al. - Researchers investigated if serum apolipoprotein J (ApoJ) levels might predict the progression to Alzheimer's disease (AD), vascular dementia (VD), or mixed dementia (AD&VD) in people with mild cognitive impairment (MCI). They recorded serum ApoJ levels in 196 MCI patients (aged ≥60 years) with a median follow up of 2.9 years. Total 132 of the overall MCI patients converted to dementia. Of these, development of AD occurred in 45%, mixed dementia in 33%, VD (VD) in 13%, and other forms of dementia developed in 9%. Findings revealed that elevated risk of developing dementia may exist in relation to low APOJ levels in individuals with MCI.